流感新型黏膜疫苗的研究

目的评价PorA、PorB和Class4对流感裂解疫苗的免疫增强作用,从中挑选出最有效的流感黏膜佐剂,为发展流感黏膜疫苗提供理论基础。方法流感三价裂解抗原按比例与PorA、PorB和Class4非共价结合,滴鼻免疫Balb／c小鼠3次,采取间接ELISA检测血清特异性IgG抗体及抗体亚型,检测鼻咽、肺、小肠和阴道冲洗液中IgA效价,采用血凝抑制试验检测血清中HAI效价。结果PorB重组蛋白佐剂组较无佐剂的流感裂解抗原组在提高小鼠早期免疫应答的同时诱导较强的系统免疫应答和黏膜免疫应答;PorA组也有黏膜佐剂的功能,但和无佐剂的流感裂解抗原组相比,差异无统计学意义。结论在蛋白体的三分子中,以PorB为佐剂的流感黏膜疫苗不仅提高了抗原的系统免疫应答,而且诱导了较强的小鼠呼吸道、生殖道的局部黏膜免疫应答,为流感黏膜疫苗的研制奠定了理论基础。     

疟疾疫苗佐剂能改进rDNA疫苗

设在美国首都华盛顿的Walter Reed陆军研究所(为纪念陆军军医W.Reed而设——译者注)的研究人员正在研究一种自己研制的,可提高对疟疾抗原免疫应答的佐剂。你如果需要提高rDNA的免疫原性,不妨一试。此佐剂不仅能提高小鼠抗体水平达10至100倍,还可用来提高其它疫苗的免疫应答。该所研究人员特意为疟疾CS(环子孢子)抗原和由脑膜炎球菌外膜蛋白制备的高纯度蛋白体进行了疏水性复合。蛋白体作为B组脑膜炎球菌疫苗的一个组分已在许多人身上安全     

PPS纳米颗粒作为鼻内免疫的通用投递系统

<正>以聚丙烯硫化物为基本物质的可降解性多聚体纳米颗粒(NPs,50 nm)通过可逆的二硫键与硫化的抗原和佐剂蛋白结合,并评价其在黏膜免疫接种中的作用。以卵白蛋白作为模型抗原,结合了抗原的NPs鼻内免疫小鼠,作者证明,能穿透鼻黏膜,能被     

添加脂质体和明矾佐剂的戊肝病毒的重组中和表位蛋白免疫小鼠的不同免疫效应

<正>在发展中国家,戊型肝炎病毒是引起成人散发型肝炎和造成孕妇高死亡率的水源性流行病的优势病原体。疫苗的研发主要关注病毒开放阅读框-2的结构衣壳蛋白。作者成功地评价了小鼠和恒河猴体内的以脂质体为佐剂的重组中和表位蛋白,即开放阅读框-2的一部分的免疫原性,它编码458~607位氨基酸。用5μg/次的剂量肌注小鼠两次,分别比较佐剂、中和表位蛋白、添加脂质体佐剂/明矾佐剂的免疫效应。     

马槟榔甜味蛋白的研究—Ⅲ.在种子中储存的位点和状态

甜蛋白mabinlin是马槟榔(Capparis masaikai Levl.)种子的主要储存蛋白。它位于胚轴细胞的蛋白体中,其含量为蛋白体总蛋白的90％。圆形蛋白体直径约2—10μm,内含许多球粒体(globoid),但无类晶体(crystalloid)。作为一种强碱性清蛋白,甜蛋白与一种强酸性化合物2-羟乙基葡硫甙磺酸(2-hydroxy-ethyl-glucosinolate)结合为可溶性盐,组成蛋白体的衬质(matrix)。衬质中还有酸性磷酸酯酶。球粒体无一定大小,主要含植酸钾盐。当种子或种子脱脂干粉在水中匀浆时,大部分甜蛋白与植酸结合为沉淀而不能被提取。但甜蛋白-植酸复合物溶于大于0.5N的氯化钠溶液。这容易引起以为种子主要储存蛋白是球蛋白的假象。在水浸泡的完整种子中,部分甜蛋白从蛋白体中渗出,部分与植酸结合而后逐步释放,受到进一步降解。     

拟南芥菜(Arabidopsis thaliana)子叶中蛋白体形成的超微结构和免疫电镜定位研究

本文对拟南芥菜(Arabidopsis thaliana)种子发育过程中贮藏蛋白的积累和蛋白体的形成进行了超微结构和免疫电镜定位的研究。常规超薄切片的电镜观察表明,在开花后第10天(10 DAF),高电子密度的蛋白质物质开始在子叶细胞的液泡中沉积。这一过程一直延续到种子接近成熟(14 DAF),这时液泡中充满了蛋白质物质,转变成为大的蛋白体。利用了该种植物主要种子贮藏蛋白之一的12 s球蛋白的单克隆抗体作为免疫探针,以蛋白质A-胶体金电镜技术对12 s种子蛋白进行了细胞内定位,证实了在液泡中积累的物质为种子贮藏蛋白。实验结果表明在拟南芥菜中,子叶细胞中的液泡是蛋白体的前体,肯定了蛋白体的发生起源于液泡的观点。本文还对应用胶体金电镜技术进行细胞内定位的某些问题作了初步探讨。     

细菌样颗粒——新型乳酸菌表面展示技术及其应用

细菌样颗粒(Bacterium-like particles,BLPs)是一种新型非遗传修饰型乳酸菌表面展示技术,外源蛋白可通过锚钩蛋白锚定于经热酸处理而得的乳酸菌肽聚糖骨架表面,形成空心表面展示颗粒。因其安全性高、表面展示密度大、黏膜递送效率高,又兼有佐剂效应,BLPs广泛应用于黏膜疫苗和黏膜佐剂的开发、病毒抗原的纯化、生物催化剂的制备等领域。本文就BLPs的构建、独特优势、目前的应用及尚需解决的问题等方面进行详细综述,以期展现BLPs新型表面展示平台的广阔应用前景。     

植物贮藏蛋白体的形成与发育及其调控

植物贮藏蛋白体由质体、内质网及液泡发育而来。贮藏蛋白体的形成和发育受贮藏蛋白质组分,蛋白质多肽携带信号,植物凝集素及一些细胞器的调控。贮藏蛋白体是由单层膜包围的亚细胞结构,其主要成份是贮藏蛋白质,植酸、植物凝集素,一些酶及无机离子如K~+Mg~(2+)等。贮藏蛋白体的形成与发育研究受到了人们的注意。本文将介绍一些这方面的进展。一、贮藏蛋白体的形成与发育贮藏蛋白体被认为是由质体,内质网和液泡发育而来,更多的资料支持后两种观点。 1、质体Graham发现玉米贮藏蛋白体形成与细胞质膜有关,这些蛋白体有双层膜结构。Morton将它们称为蛋白质体。分离的蛋白质体能在体外合成贮藏蛋白质,     

不同佐剂对人乳头瘤病毒16型L2E7E6蛋白免疫效果的影响

目的:研究CpG佐剂、弗氏佐剂、聚肌胞苷酸佐剂及左旋咪唑、西米替丁作为佐剂对人乳头瘤病毒16型L2E7E6融合蛋白在小鼠体内产生的免疫效果的影响。方法:以单独蛋白组、蛋白加各佐剂组分别肌肉注射免疫C57BL/6小鼠,检测不同佐剂诱发小鼠产生的体液免疫和细胞免疫应答水平,并观察其对小鼠肿瘤生长的抑制作用。结果:各免疫组均能检测到高滴度的抗L2、E7、E6蛋白IgG抗体(以IgG1为主),其中弗氏佐剂能显著提高E6蛋白的IgG和IgG1抗体水平和E7蛋白的IgG1抗体水平(P<0.05),CpG佐剂明显提高了E7蛋白的IgG2a抗体水平(P<0.01);而西米替丁佐剂则降低了E7抗原的IgG抗体水平(P<0.05);同时可以检测到CpG佐剂组能诱发小鼠产生针对E7、E6较强的细胞免疫反应,且能抑制70%的荷瘤小鼠肿瘤生长;此外弗氏佐剂与聚肌胞苷酸佐剂可产生较弱的针对E7肽的细胞免疫反应,能延缓荷瘤小鼠肿瘤形成时间,与单纯蛋白组相比差异显著(P<0.05)。结论:CpG佐剂、弗氏佐剂和聚肌胞苷酸佐剂都能提高人乳头瘤病毒16型L2E7E6融合蛋白的细胞免疫反应水平和抑制肿瘤生长能力,其中CpG佐剂效果较好,为促进该蛋白作为疫苗的研发提供了实验依据。     

燕麦糊粉细胞在种子萌发前后的亚显微结构

对燕麦糊粉细胞在种子萌发0,1,2,3,4,5,6,7天的亚显微结构进行了观察。重点观察了有关燕麦糊粉细胞内的蛋白体和糊粉细胞的胞壁在萌发过程中的变化情形。种子未萌发时,糊粉细胞内的蛋白体含有浓密的蛋白质基质和植酸钙镁以及蛋白-糖复合体两种内含体。种子萌发时,蛋白体内的蛋白质基质和植酸钙镁逐渐消失,而蛋白-糖复合体的消失则稍为缓慢。到萌发7天时,蛋白体都基本转化为液泡。糊粉细胞的胞壁在种子未萌发时具有内外两层壁结构。但在种子萌发时,外壁逐渐被水解而消失;但内壁则保持不变。文中还描述和讨论了有关糊粉细胞内壁和外壁的一些特性和功能。     

Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses

Recombinant Norwalk virus-like particles (rNV VLPs) were administered to BALB/c mice by the intranasal (i.n.) route to evaluate the induction of mucosal antibody responses. The results were compared to systemic and mucosal responses observed in new and previous studies (J. M. Ball, M. E. Hardy, R. L. Atmar, M. E. Connor, and M. K. Estes, J. Virol. 72:1345-1353, 1998) after oral administration of rNV VLPs. Immunizations were given in the presence or absence of a mucosal adjuvant, mutant Escherichia coli heat-labile toxin LT(R192G). rNV-specific immunoglobulin G (IgG) and fecal IgA were evaluated by enzyme-linked immunosorbent assay. The i.n. delivery of rNV VLPs was more effective than the oral route at inducing serum IgG and fecal IgA responses to low doses of rNV particles. Vaginal responses of female mice given VLPs by the i.n. and oral routes were also examined. All mice that received two immunizations with low doses i.n. (10 or 25 microg) of rNV VLPs and the majority of mice that received two high doses orally (200 microg) in the absence of adjuvant had rNV-specific serum IgG, fecal, and vaginal responses. Additional experiments evaluated whether rNV VLPs can function as a mucosal adjuvant by evaluating the immune responses to two soluble proteins, keyhole limpet hemocyanin and chicken egg albumin. Under the conditions tested, rNV VLPs did not enhance the serum IgG or fecal IgA response to these soluble proteins when coadministered by the i.n. or oral route. Low doses of nonreplicating rNV VLPs are immunogenic when administered i.n. in the absence of adjuvant, and addition of adjuvant enhanced the magnitude and duration of these responses. Recombinant NV VLPs represent a candidate mucosal vaccine for NV infections in humans.     

Current prophylactic and therapeutic uses of a recombinant Lactococcus lactis strain secreting biologically active interleukin-12

The noninvasive and food-grade Gram-positive bacterium Lactococcus lactis is well adapted to deliver medical proteins to the mucosal immune system. In the last decade, the potential of live recombinant lactococci to deliver such proteins to the mucosal immune system has been investigated. This approach offers several advantages over the traditional systemic injection, such as easy administration and the ability to elicit both systemic and mucosal immune responses. This paper reviews the current research and advances made with recombinant L. lactis as live vector for the in situ delivery of biologically active interleukin-12, a potent pleiotropic cytokine with adjuvant properties when co-delivered with vaccinal antigens, at mucosal surfaces. Three well-illustrated examples demonstrate the high potential of interleukin-12-secreting lactococci strains for future prophylactic and therapeutic uses.     

The proteosomal degradation of fusion proteins cannot be predicted from the proteosome susceptibility of their individual components

It is assumed that the proteosome-processing characteristics of fusion constructs can be predicted from the sum of the proteosome sensitivity of their components. In the present study, we observed that a fusion construct consisting of proteosome-degradable proteins does not necessarily result in a proteosome-degradable chimera. Conversely, fusion of proteosome-resistant proteins may result in a proteosome-degradable composite. We previously demonstrated that conserved influenza proteins can be unified into a single fusion antigen that is protective, and that vaccination with combinations of proteosome-resistant and proteosome-degradable antigens resulted in an augmented T-cell response. In the present study we constructed proteosome-degradable mutants of conserved influenza proteins NP, M1, NS1, and M2. These were then fused into multipartite proteins in different positions. The stability and degradation profiles of these fusion constructs were demonstrated to depend on the relative position of the individual proteins within the chimeric molecule. Combining unstable sequences of either NP and M1 or NS1 and M2 resulted in either rapidly proteosome degraded or proteosome-resistant bipartite fusion mutants. However, further unification of the proteosome-degradable forms into a single four-partite fusion molecule resulted in relatively stable chimeric proteins. Conversely, the addition of proteosome-resistant wild-type M2 to proteosome-resistant NP-M1-NS1 fusion protein lead to the decreased stability of the resulting four-partite multigene products, which in one case was clearly proteosome dependent. Additionally, a highly destabilized form of M1 failed to destabilize the wild-type NP. Collectively, we did not observe any additive effect leading to proteosomal degradation/nondegradation of a multigene construct.     

霍乱弧菌CTB基因的克隆、表达及重组蛋白活性分析

霍乱弧菌CTB蛋白具有免疫佐剂活性。本研究根据已发表CTB基因的序列设计一对引物,从一株霍乱弧菌中扩增出CTB基因,测序后发现该基因全长375 bp,与国内分离的六株CTB基因的同源性达96.0%～99.2%。将该基因与pTWIN1连接构建了原核表达载体pTWIN1-CTB,重组表达载体转化BL21（DE3）表达菌株,0.8 mmol/L IPTG诱导4 h后,收获的细菌总蛋白SDS-PAGE电泳显示CTB在原核表达系统中得到表达,融合蛋白大小与理论值符合,蛋白产量占细菌总蛋白的20%左右,主要以包涵体形式存在,western杂交和GM1-ELISA结果表明重组蛋白具有免疫原性和粘膜佐剂活性。     

泛素蛋白酶体途径及其对植物生长发育的调控

泛素蛋白酶体途径主要由泛素活化酶、泛素结合酶、泛素蛋白连接酶和26S蛋白酶体组成。泛素活化酶首先激活泛素分子,然后把泛素转移到泛素结合酶上。泛素结合酶结合泛素蛋白连接酶并把泛素转移到底物蛋白上使底物泛素化,或把泛素转移到泛素蛋白连接酶再使底物泛素化。泛素化的蛋白通常通过26S蛋白酶体进行降解。初步的研究结果表明,植物生长发育的很多方面受泛素蛋白酶体介导的蛋白降解途径的调控。     

泛素蛋白酶体途径及其对植物生长发育的调控

泛素蛋白酶体途径主要由泛素活化酶、泛素结合酶、泛素蛋白连接酶和26S蛋白酶体组成。泛素活化酶首先激活泛素分子, 然后把泛素转移到泛素结合酶上。泛素结合酶结合泛素蛋白连接酶并把泛素转移到底物蛋白上使底物泛素化, 或把泛素转移到泛素蛋白连接酶再使底物泛素化。泛素化的蛋白通常通过26S蛋白酶体进行降解。初步的研究结果表明, 植物生长发育的很多方面受泛素蛋白酶体介导的蛋白降解途径的调控。     

The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells

The cholera toxin A1 (CTA1)-DD/QuilA-containing, immune-stimulating complex (ISCOM) vector is a rationally designed mucosal adjuvant that greatly potentiates humoral and cellular immune responses. It was developed to incorporate the distinctive properties of either adjuvant alone in a combination that exerted additive enhancing effects on mucosal immune responses. In this study we demonstrate that CTA1-DD and an unrelated Ag can be incorporated together into the ISCOM, resulting in greatly augmented immunogenicity of the Ag. To demonstrate its relevance for protection against infectious diseases, we tested the vector incorporating PR8 Ag from the influenza virus. After intranasal immunization we found that the immunogenicity of the PR8 proteins were significantly augmented by a mechanism that was enzyme dependent, because the presence of the enzymatically inactive CTA1R7K-DD mutant largely failed to enhance the response over that seen with ISCOMs alone. The combined vector was a highly effective enhancer of a broad range of immune responses, including specific serum Abs and balanced Th1 and Th2 CD4(+) T cell priming as well as a strong mucosal IgA response. Unlike unmodified ISCOMs, Ag incorporated into the combined vector could be presented by B cells in vitro and in vivo as well as by dendritic cells; it also accumulated in B cell follicles of draining lymph nodes when given s.c. and stimulated much enhanced germinal center reactions. Strikingly, the enhanced adjuvant activity of the combined vector was absent in B cell-deficient mice, supporting the idea that B cells are important for the adjuvant effects of the combined CTA1-DD/ISCOM vector.     

Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection

We demonstrated previously that the incorporation of a membrane-anchored form of flagellin into influenza virus-like particles (VLPs) improved the immunogenicity of VLPs significantly, inducing partially protective heterosubtypic immunity by intramuscular immunization. Because the efficacy of mucosal vaccination is highly dependent on an adjuvant, and is particularly effective for preventing mucosal infections such as influenza, we determined whether the membrane-anchored flagellin is an efficient adjuvant for VLP vaccines by a mucosal immunization route. We compared the adjuvant effect of membrane-anchored and soluble flagellins for immunization with influenza A/PR8 (H1N1) VLPs by the intranasal route in a mouse model. The results demonstrate that membrane-anchored flagellin is an effective adjuvant for intranasal (IN) immunization, inducing enhanced systemic and mucosal antibody responses. High cellular responses were also observed as shown by cytokine production in splenocyte cultures when stimulated with viral antigens. All mice immunized with flagellin-containing VLPs survived challenge with a high lethal dose of homologous virus as well as a high dose heterosubtypic virus challenge (40 LD(50) of A/Philippines/82, H3N2). In contrast, no protection was observed with a standard HA/M1 VLP group upon heterosubtypic challenge. Soluble flagellin exhibited a moderate adjuvant effect when co-administered with VLPs by the mucosal route, as indicated by enhanced systemic and mucosal responses and partial heterosubtypic protection. The membrane-anchored form of flagellin incorporated together with antigen into influenza VLPs is effective as an adjuvant by the mucosal route and unlike standard VLPs, immunization with such chimeric VLPs elicits protective immunity to challenge with a distantly related influenza A virus.     

Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA

Synthetic oligodeoxynucleotides (ODN) containing immunostimulatory CpG motifs (CpG ODN) are potent adjuvants to protein antigens administered by parenteral or mucosal routes to BALB/c mice. To date, there have been no studies using combined parenteral/mucosal approaches with CpG DNA as adjuvant. In this study we evaluated different parenteral prime-mucosal boost and mucosal prime-parenteral boost strategies using hepatitis B surface antigen (HBsAg) alone or with different adjuvants: aluminum hydroxide (alum), cholera toxin (CT), CpG ODN. In addition, since CpG ODN has previously been shown to act synergistically with other adjuvants after parenteral or mucosal delivery, we also evaluated adjuvant combinations: alum+CpG ODN and CT+CpG ODN. The effects of adjuvant and administration strategy on systemic and mucosal humoral responses were measured, as well as cell-mediated immune responses (cytotoxic T lymphocyte activity). These results were compared to parenteral only or mucosal only strategies. Our findings demonstrate that parenteral immunization can prime for mucosal responses even when different lymph nodes were being targeted. HBsAg-specific immune responses (IgG in plasma, cytotoxic T lymphocytes) induced by parenteral prime could all be significantly enhanced by mucosal boosting and despite the fact that intramuscular immunization alone could not induce mucosal IgA, it could prime for a subsequent mucosal boost. In addition, the presence of adjuvant at time of boosting could influence the nature of subsequent immune responses (Th1 vs. Th2). Mice primed intranasally could have their systemic immune responses boosted with a parenteral administration and it was also possible to enhance mucosal responses induced by intranasal prime with an intramuscular boost.     

Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization

Safe and potent new adjuvants are needed for vaccines that are administered to mucosal surfaces. This study was performed to determine if interleukin-1alpha (IL-1alpha) combined with other proinflammatory cytokines provided mucosal adjuvant activity for induction of systemic and mucosal anti-human immunodeficiency virus (HIV) peptide antibody when intranasally administered with an HIV peptide immunogen. Nasal immunization of BALB/c mice with 10 microg of an HIV env peptide immunogen with IL-1alpha, IL-12, and IL-18 on days 0, 7, 14, and 28 induced peak serum anti-HIV peptide immunoglobulin G1 (IgG1) and IgA titers of 1:131,072 and 1:7,131, respectively (P = 0.05 versus no adjuvant). The use of cholera toxin (CT) as a mucosal adjuvant induced serum IgG1 and IgA titers of 1:32,768 and 1:776, respectively. The adjuvant combination of IL-1alpha, IL-12, and IL-18 induced anti-HIV peptide IgA titers of 1:1,176, 1:7,131, and 1:4,705 in saliva, fecal extracts and vaginal lavage, respectively. Titers induced by the use of CT as an adjuvant were 1:223, 1:1,176, and 1:675, respectively. These results indicate that the proinflammatory cytokines IL-1alpha, IL-12, and IL-18 can replace CT as a mucosal adjuvant for antibody induction and are important candidates for use as mucosal adjuvants with HIV and other vaccines.